Zunsemetinib
202502144
Phase 1 small_molecule active
Quick answer
Zunsemetinib for Metastatic Pancreatic Ductal Adenocarcinoma is a Phase 1 program (small_molecule) at Aclaris Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aclaris Therapeutics
- Indication
- Metastatic Pancreatic Ductal Adenocarcinoma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active